Advertisement

Topics

Advicenne Company Profile

15:36 EDT 25th June 2019 | BioPortfolio

Advicenne (Euronext: ADVIC) is a pharmaceutical company developing pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company’s lead product is ADV7103 which has demonstrated positive results in a European pivotal phase 3 study in children and adults with distal Tubular Renal Acidosis (dTRA), is also being developed for a second indication, Cystinuria, an inherited renal tubulopathy.


News Articles [7 Associated News Articles listed on BioPortfolio]

Why Advicenne's Kidney Disease Drug Reverted To Standard EU Review

The CEO of French firm Advicenne explains why the company did not win an accelerated EU assessment for its kidney...   

Advicenne raised a €27m IPO on Euronext Paris

Advicenne Prepares For Launch As Rare Kidney Disease Drug Is Filed In The EU

Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard...   

Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)

Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC – FR0013296746), specializing in the development of adult and pediatric therapeutic products for the tr...

Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium

Authorization extends patient recruitment base of European Phase II/III CORAL study, previously authorized in France Regulatory News: Advicenne (Paris:ADVIC) (...

Advicenne SA ADVIC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27082018] Prices from USD $250

SummaryAdvicenne SA Advicenne is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic...

Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC - FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric the...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Advicenne

Advicenne (Euronext: ADVIC) is a pharmaceutical company developing pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company’s ...

More Information about "Advicenne" on BioPortfolio

We have published hundreds of Advicenne news stories on BioPortfolio along with dozens of Advicenne Clinical Trials and PubMed Articles about Advicenne for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Advicenne Companies in our database. You can also find out about relevant Advicenne Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record